Adlai Nortye
Adlai Nortye engages in research and development of biopharmaceuticals for cancer immunotherapy.
Launch date
Employees
Market cap
CAD115m
Enterprise valuation
CAD36m (Public information from Sep 2024)
Share price
$2.1 ANL
Hangzhou Zhejiang (HQ)
Authorizing premium user...